| Literature DB >> 32550570 |
Luis Román-Domínguez1,2, Edgar Neri-Castro1, Hilda Vázquez López1, Belem García-Osorio1, Irving G Archundia1, Javier A Ortiz-Medina3,4, Vera L Petricevich5, Alejandro Alagón1, Melisa Bénard-Valle1.
Abstract
In the present work, venoms from five species of the genus Agkistrodon were evaluated in terms of their enzymatic (Phospholipase A2 and caseinolytic) and biological (edema forming, hemorrhagic, procoagulant and lethal) effects. Horses were used to produce monovalent hyperimmune sera against each of three venoms (A. bilineatus, A. contortrix and A. piscivorus) and their neutralizing potency, expressed as Median Effective Dose (ED50), was determined against the venoms of all five species. In terms of PLA2 and caseinolytic activities, all venoms are extremely homogeneous. PLA2 activity is high, while caseinolytic activity is low when in contrast with that of the rattlesnake Crotalus simus. On the other hand, biological activities showed marked interspecific differences, particularly between the species from Mexico and those from the United States. Mexican species displayed higher edema-forming, hemorrhagic and lethal effects than US species, while none of the species studied presented procoagulant activity. All three monovalent hyperimmune sera showed good neutralizing potency against the analyzed venoms. Nonetheless, we observed relevant immunochemical differences among the venoms using ELISA and Western Blot assays. We conclude that the venoms of A. piscivorus (USA) and A. bilineatus would be ideal to use as immunogens for the production of a polyvalent antivenom with good neutralizing potency against the venoms of all the species of the genus.Entities:
Keywords: Agkistrodon venoms; Antivenom neutralization; Edema; Hemorrhage; Immunochemistry
Year: 2019 PMID: 32550570 PMCID: PMC7285990 DOI: 10.1016/j.toxcx.2019.100013
Source DB: PubMed Journal: Toxicon X ISSN: 2590-1710
Fig. 1Distribution of species of the genus Colored areas represent the distribution of the species modified from (Campbell and Lamar, 2004, Porras et al., 2013). Diagonal lines represent areas where both A. contortrix and A. piscivorus are present. A. c. contortrix photo by Eric Centenero. (This map is not to scale; it is only meant for illustrative purposes).
Individual venoms used for characterization and hyperimmunization pools.
| A. Venom characterization Pools | ||||
|---|---|---|---|---|
| Pool | Species | Herpetarium | State of origin | Venom dry weight (mg) |
| DeVal Animal | Colima, MX | 8 | ||
| DeVal Animal | Nayarit, MX | 8 | ||
| IBt-UNAM | Nayarit, MX | 8 | ||
| FC-UNAM | Chiapas, MX | 8 | ||
| FC-UNAM | Chiapas, MX | 8 | ||
| IBt-UNAM | Tamaulipas, MX | 6 | ||
| IBt-UNAM | Yucatán, MX | 3 | ||
| IBt-UNAM | Yucatán, MX | 3 | ||
| NNTRC | Texas, US | 1.5 | ||
| “TSÁAB KAAN” | Florida, US | 1.5 | ||
| “TSÁAB KAAN” | Florida, US | 1.5 | ||
| NNTRC | Texas, US | 1.5 | ||
| “Reptiles Fergo" | Unknown | 1.5 | ||
| NNTRC | Texas, US | 6 | ||
Venom pool.
Fig. 2SDS-PAGE profile of Reducing conditions (2 ME). MWM. Molecular weight markers.
Fig. 3RP-HPLC of analytic column.mAU. Milli Absorbance Units at 214 nm % B. Percentage of buffer B (CH3CN + 0.1% TFA).
Enzymatic and pharmacological activities of Agkistrodon venom pools.
| PLA2 | Proteolysis | MED | MHD | MPD-HP | LD50 | ||
|---|---|---|---|---|---|---|---|
| (U/mg ± SD) | (U/mg ± SD) | (μg ± SD) | (μg ± SD) | (μg) | (μg/mouse) | (μg/g) | |
| 383.2 ± 97.7 | 6.8 ± 1.3 | 0.2 ± 0.01 | 0.8 ± 0.04 | >100 | 36.5 (36–37.1) | 1.9 | |
| 720.2 ± 81 | 6.4 ± 0.6 | 0.1 ± 0.01 | 0.7 ± 0.25 | >100 | 26.2 (22.7–30.6) | 1.4 | |
| 371.5 ± 146.3 | 5.2 ± 0.7 | 0.1 ± 0.03 | 0.3 ± 0.06 | >100 | 22.3 (22.2–22.3) | 1.2 | |
| 296.8 ± 64.9 | 7.0 ± 1.0 | 1.8 ± 1.2 | 33.8 ± 1.4 | >100 | 215.4 (197.0–235.5) | 11.3 | |
| 231.9 ± 49.3 | 6.4 ± 0.6 | 3.6 ± 0.5 | 7.4 ± 0.74 | >100 | 96.6 (92.6–100.9) | 5.1 | |
| ND | 11.2 ± 1.6 | 10.0 ± 1.2 | 25.1 ± 1.3 | ND | 3.8 (3.4–3.9) | 0.2 | |
Phospholipase A2 activity on 10% egg yolk.
Proteolytic activity on azocasein.
Minimum edema-forming dose.
Minimum hemorrhagic dose.
Minimum procoagulant dose on human plasma.
Median lethal dose, values in parenthesis represent 95% confidence intervals.
Units of enzymatic activity per milligram of venom ± standard deviation.
Not determined.
(Castro et al., 2013).
Antibody titers and neutralization potency of produced sera against Agkistrodon venoms.
| LD50 | Serum 201 [anti- | Serum 202 [anti- | Serum 203 [anti- | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Titer | ED50 | Titer | ED50 | Titer | ED50 | |||||
| μg/g | mgV/mLS | LD50/mLS | mgV/mLS | LD50/mLS | mgV/mLS | LD50/mLS | ||||
| 1.9 | 18,467 | 0.5 (0.5–0.6) | 15.8 | 15,821 | 0.5 (0.4–0.6) | 14.2 | ||||
| 1.4 | 41,131 | 0.9 (0.9–0.9) | 33.5 | 44,780 | 0.3 (0.3–0.4) | 12.6 | 122,525 | 0.2 (0.2–0.3) | 9.4 | |
| 1.2 | 34,457 | 1.5 (1.4–1.5) | 65.1 | 49,880 | 2.0 (1.6–2.4) | 89.1 | 121,043 | 5.1 (4.9–5.4) | 229.5 | |
| 11.3 | 30,528 | 2.5 (2.1–3.0) | 11.8 | 33,522 | 2.0 (1.7–2.4) | 9.4 | ||||
| 5.1 | 23,278 | 1.1 (1.0–1.3) | 11.8 | 43,676 | 0.9 (0.9–1.0) | 9.7 | ||||
| 6.1 | 20,755 | 1.4 (1.3–1.5) | 11.8 | 61,035 | 2.1 (1.6–2.8) | 17.7 | ||||
| 6.3 | 29,829 | 1.1 (1.0–1.1) | 9.0 | 67,872 | 2.2 (2.0–2.4) | 18.5 | ||||
| Numbers in parenthesis represent 95% confidence intervals. Values in bold represent responses to the homologous venom. | ||||||||||
Median lethal dose.
Neutralization median effective dose, using 3LD50s of venom.
Milligrams of venom neutralized per milliliter of serum.
Median lethal doses of venom neutralized per milliliter of serum.
Fig. 4Percentage of competition of each horse serum with A higher inhibition percentage shows more shared epitopes between the homologous and tested venom.
Type of PLA2s present in Agkistrodon venoms.
| % D49 | % K49 | MED | PLA2 | |
|---|---|---|---|---|
| 16.9 | 17.9 | 0.2 | 383.2 | |
| 26.5 | 7.8 | 0.1 | 720.2 | |
| 9.8 | 21.7 | 1.8 | 296.8 | |
| 24.0 | 12.8 | 3.6 | ||
| 28.6 | 14.6 | 231.9 | ||
| 28.7 | 17.3 |
Percentage data were obtained from Lomonte et al. (2014).
Minimum Edema-forming Dose (micrograms).
PLA2 enzymatic activity (Units per milligram).
Activity determined using a pool of the three subspecies.
Metalloprotease type in Agkistrodon venoms.
| Group | SVMPs % | |
|---|---|---|
| P–I | 29.7 | 1.9 |
| P-II | 2.3 | 28.1 |
| P-III | 0.5 | 0.6 |
Adapted from Lomonte et al. (2014).
Fig. 5Progression of edema on mouse paw injected subcutaneously with different Percentage represents increased diameter compared to the contralateral paw (See Materials and Methods).